Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

Overview

The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation following primary CABG and/or valve surgery and compare a number of secondary outcomes.

Full Title of Study: “Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery: A Prospective Randomized Controlled Pilot Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 1, 2024

Detailed Description

Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery. Patients in the control group will receive no block and undergo surgery with routine anesthetic care guided by their cardiac anesthesiologist.

Interventions

  • Drug: Ropivacaine 0.2% Injectable Solution
    • Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.

Arms, Groups and Cohorts

  • Experimental: Experimental
    • Participants in this group will receive the intervention.
  • No Intervention: Control
    • Participants in this group will receive no intervention.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of New-Onset Atrial Fibrillation (NOAF)
    • Time Frame: 5 days
    • The primary outcome for this trial is the incidence of new-onset atrial fibrillation (NOAF) in the first 5 days following cardiac surgery, defined as atrial fibrillation and/or flutter as recorded on a 12-lead ECG or rhythm strip for greater than 30 seconds in patients with no prior history of atrial fibrillation and/or flutter. Outcome is reported as the percent of participants with NOAF in each arm.

Secondary Measures

  • Cumulative Opioid Use – Average Dosages
    • Time Frame: 24, 48, 72, 96, and 120 hours post-operatively
    • Outcome reported as the average opioid dosage at 24, 48, 72, 96, and 120 hours post-operatively.
  • Cumulative Opioid Use – Morphine Equivalents
    • Time Frame: 24, 48, 72, 96, and 120 hours post-operatively
    • Outcome reported as the cumulative opioid use in morphine milligram equivalents at 24, 48, 72, 96, and 120 hours post-operatively.
  • Time to Extubation
    • Time Frame: approximately 5 days
    • Outcome reported as the amount of time (in hours) participants remain intubated post-operatively.
  • Intensive Care Unit (ICU) Length of Stay
    • Time Frame: approximately 5 days
    • Outcome reported as the length of time (in days) that participants are admitted to the intensive care unit (ICU) post-operatively.
  • Hospital Length of Stay
    • Time Frame: approximately 7 days
    • Outcome reported as the length of time (in days) that participants remain admitted to the hospital post-operatively.
  • 30-Day Mortality
    • Time Frame: 30 days
    • Outcome reported as the percent of participants in each arm who expire in the 30 days following surgery.
  • Cumulative ICU sedation doses
    • Time Frame: 24 and 72 hours post-operatively
    • Outcome reported as the cumulative doses of sedatives (Midazolam, Fentanyl, Propofol, Dexmedetomidine, Haloperidol, Olanzapine) at 24 hours and 72 hours post-operatively.
  • Diagnosis of delirium during index hospitalization
    • Time Frame: approximately 7 days
    • Outcome reported as the percent of participants in each arm who are diagnosed with delirium during hospital admission.
  • Quality of Recovery 15 (QOR-15) Scores
    • Time Frame: 24, 48, 72, 96, and 120 hours post-operatively
    • The Quality of Recovery 15 is a 15-item survey evaluating recovery after surgery and anaesthesia. Items are rated on a scale 0-10. Total scores are a sum of item scores and range 0-150, with higher scores representing a higher quality of recovery.
  • Average pain score
    • Time Frame: 24, 48, 72, 96, and 120 hours post-operatively
    • Participants will be asked to rate their pain on a scale from 0 (no pain) to 10 (maximum pain imaginable).
  • Block-associated complications
    • Time Frame: approximately 5 days
    • Outcome reported as the number of block-associated complications including catheter infection, vascular puncture, bleeding that results in neurologic compromise, pneumothorax.
  • Block performance time
    • Time Frame: approximately 1 hour
    • Outcome reported as the length of time (in minutes) for placement of catheters.
  • Duration of vasopressor requirement
    • Time Frame: approximately 24 hours
    • Outcome reported as the length of time (in hours) that participants require vasopressor therapy.

Participating in This Clinical Trial

Inclusion Criteria

  • Participants must be undergoing one of the following elective or urgent (but not emergent) surgeries: A) Primary Coronary Artery Bypass Graft (CABG) B) Primary Surgical Aortic Valve Replacement (sAVR) C) Primary Surgical Mitral Valve Replacement (sMVR) D) Combined CABG & surgical valve replacement Exclusion Criteria:

  • History of atrial fibrillation or flutter – Infective endocarditis – Left ventricular ejection fraction (LVEF) < 30% – Emergency surgery – Redo surgery – Contraindication to block placement including local anesthetic allergy, bleeding diathesis (physiologic or iatrogenic) – Body mass index > 35kg/m2 – Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Minnesota
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • James Flaherty, MD, Principal Investigator, University of Minnesota
  • Overall Contact(s)
    • Candace Nelson, 612-626-2465, nelso377@umn.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.